Diversified Trust’s Neurocrine Biosciences NBIX Stock Holding History

Diversified Trust’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$647K	Buy	3,838 +603	+19%	+$89.5K	0.01%	673
2026 Q1	$426K	Buy	3,235 +15	+0.5%	+$1.99K	0.01%	738
2025 Q4	$457K	Buy	+3,220	New	+$466K	0.01%	687
2024 Q1	–	Sell	-2,381	Closed	-$314K	–	903
2023 Q4	$314K	Buy	2,381 +267	+13%	+$30.7K	0.01%	646
2023 Q3	$238K	Buy	+2,114	New	+$223K	0.01%	699
2023 Q2	–	Sell	-2,316	Closed	-$234K	–	883
2023 Q1	$234K	Buy	2,316 +143	+7%	+$14.9K	0.01%	715
2022 Q4	$260K	Sell	2,173 -64	-3%	-$7.5K	0.01%	635
2022 Q3	$238K	Buy	+2,237	New	+$227K	0.01%	629
2013 Q3	–	Sell	-21,960	Closed	-$294K	–	475
2013 Q2	$294K	Buy	+21,960	New	+$270K	0.04%	398

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Diversified Trust's NBIX Position: Q2 2026 in Review

Diversified Trust increased its Neurocrine Biosciences (NBIX) stake by 19% in Q2 2026, buying an estimated $89.5K and bringing the position to 3,838 shares worth $647K. The position accounts for 0.01% of the portfolio, ranked #673.

Diversified Trust first reported a position in NBIX in Q2 2013 and has held it in 9 quarters since. 84 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Diversified Trust held 3,838 shares of Neurocrine Biosciences worth $647K as of Q2 2026.
Diversified Trust bought 603 Neurocrine Biosciences shares in Q2 2026, an estimated $89.5K.
Neurocrine Biosciences made up 0.01% of Diversified Trust's portfolio in Q2 2026, its #673 holding.
Diversified Trust first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 9 quarters since.
84 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Diversified Trust's 13F filing for Q2 2026, filed 17 Jul 2026.